EA201691057A1 - Новые способы лечения нейродегенеративных заболеваний - Google Patents
Новые способы лечения нейродегенеративных заболеванийInfo
- Publication number
- EA201691057A1 EA201691057A1 EA201691057A EA201691057A EA201691057A1 EA 201691057 A1 EA201691057 A1 EA 201691057A1 EA 201691057 A EA201691057 A EA 201691057A EA 201691057 A EA201691057 A EA 201691057A EA 201691057 A1 EA201691057 A1 EA 201691057A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- neurodegenerative diseases
- new methods
- treating neurodegenerative
- treating
- dihydroorotatdehydrogenase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Настоящее изобретение относится к ингибиторам дигидрооротатдегидрогеназы (DHODH), применимым для лечения нейродегенеративных заболеваний, таких как боковой амиотрофический склероз.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908019P | 2013-11-22 | 2013-11-22 | |
PCT/US2014/066766 WO2015077535A2 (en) | 2013-11-22 | 2014-11-21 | Novel methods for treating neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201691057A1 true EA201691057A1 (ru) | 2016-10-31 |
Family
ID=52146688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691057A EA201691057A1 (ru) | 2013-11-22 | 2014-11-21 | Новые способы лечения нейродегенеративных заболеваний |
Country Status (14)
Country | Link |
---|---|
US (1) | US20160287549A1 (ru) |
EP (1) | EP3071199A2 (ru) |
JP (1) | JP2016537360A (ru) |
KR (1) | KR20160079123A (ru) |
CN (1) | CN105916522A (ru) |
AU (1) | AU2014352920A1 (ru) |
CA (1) | CA2930429A1 (ru) |
CL (1) | CL2016001192A1 (ru) |
EA (1) | EA201691057A1 (ru) |
IL (1) | IL245541A0 (ru) |
MX (1) | MX2016006678A (ru) |
PH (1) | PH12016500903A1 (ru) |
TN (1) | TN2016000197A1 (ru) |
WO (1) | WO2015077535A2 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017056104A1 (en) * | 2015-09-28 | 2017-04-06 | Natco Pharma Limited | Stable pharmaceutical compositions of teriflunomide |
CN107382902B (zh) * | 2016-05-17 | 2022-08-12 | 华东理工大学 | 噻唑类衍生物及其应用 |
US20200360324A1 (en) | 2017-11-23 | 2020-11-19 | Immunic Ag | Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases |
WO2020005189A2 (en) | 2018-06-27 | 2020-01-02 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Solid oral pharmaceutical compositions comprising teriflunomide |
US11877994B2 (en) | 2021-08-02 | 2024-01-23 | Immunic Ag | Treatment of multiple sclerosis comprising DHODH inhibitors |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL186239B (nl) | 1975-06-05 | Hoechst Ag | Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze. | |
US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
DE3483704D1 (de) | 1983-07-22 | 1991-01-17 | Du Pont | Phenylchinolinsaeure und derivate als antitumormittel. |
US4680299A (en) | 1984-04-30 | 1987-07-14 | E.I. Du Pont De Nemours And Company | 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof |
US5032597A (en) | 1983-07-22 | 1991-07-16 | Du Pont Merck Pharmaceutical | Method of using phenylquinolinecarboxylic acids and derivatives for lymthoid leukemia treatment in a mammal |
US4639454A (en) | 1985-01-17 | 1987-01-27 | E. I. Du Pont De Nemours And Company | Phenylquinazolinecarboxylic acids and derivatives as cancer chemotherapeutic agents |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
GB8619432D0 (en) | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
GB8619433D0 (en) | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4816540A (en) | 1987-06-12 | 1989-03-28 | Yasuhiko Onishi | Cationic graft-copolymer |
US4847381A (en) | 1987-08-31 | 1989-07-11 | American Cyanamid Company | 2-Phenyl-4-quinoline carboxylic acids |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
US4968701A (en) | 1988-04-26 | 1990-11-06 | E. I. Du Pont De Nemours And Company | 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents |
US4861783A (en) | 1988-04-26 | 1989-08-29 | E. I. Du Pont De Nemours And Company | 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases |
US4968702A (en) | 1989-01-17 | 1990-11-06 | American Cyanamid Company | Substituted quinolinecarboxylic acids |
US4918077A (en) | 1989-01-25 | 1990-04-17 | E. I. Du Pont De Nemours & Co., Inc. | 3-phenyl-5,6-dihydrobenz(c)acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents |
US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
AU649421B2 (en) | 1990-05-18 | 1994-05-26 | Sanofi-Aventis Deutschland Gmbh | Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs |
US5204329A (en) | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
US5135934A (en) | 1990-07-06 | 1992-08-04 | Du Pont Merck Pharmaceutical Company | 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents |
US5198223A (en) | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
IL99811A (en) | 1990-10-30 | 1996-03-31 | Roussel Uclaf | 3-Cycloalkyl-propanamides, tautomeric forms of these, their salts, method of preparation, use as drugs and preparations containing them |
IL102790A (en) | 1991-09-17 | 1996-01-31 | Roussel Uclaf | History of 3-cycloalkyl-prop-2-anamide |
NZ244814A (en) | 1991-10-23 | 1994-06-27 | Hoechst Ag | N-phenyl-2-cyano-3-hydroxycrotonamide derivatives and pharmaceutical compositions |
GB9200275D0 (en) | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
ATE168679T1 (de) | 1992-04-24 | 1998-08-15 | Kyowa Hakko Kogyo Kk | Neue tetracyclische verbindungen |
GB9209330D0 (en) | 1992-04-30 | 1992-06-17 | Roussel Lab Ltd | Chemical compounds |
GB9300083D0 (en) | 1993-01-05 | 1993-03-03 | Roussel Lab Ltd | Chemical compounds |
WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
JP3272808B2 (ja) | 1993-04-28 | 2002-04-08 | 協和醗酵工業株式会社 | 新規四環系化合物 |
US5393891A (en) | 1993-06-08 | 1995-02-28 | The Du Pont Merck Pharmaceutical Company | Immunoassay reagents and methods for detecting brequinar and analogs |
GB9313365D0 (en) | 1993-06-29 | 1993-08-11 | Roussel Lab Ltd | Chemical compounds |
US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
EP0721942B1 (en) | 1993-09-28 | 2002-06-05 | Kyowa Hakko Kogyo Co., Ltd. | Tetracyclic compound |
GB9320299D0 (en) | 1993-10-01 | 1993-11-17 | Roussel Lab Ltd | Isoxazole derivatives |
GB9322781D0 (en) | 1993-11-04 | 1993-12-22 | Roussel Lab Ltd | Aromatic amides |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US5523408A (en) | 1994-03-25 | 1996-06-04 | The Dupont Merck Pharmaceutical Company | 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents |
JPH083163A (ja) | 1994-06-22 | 1996-01-09 | Kyowa Hakko Kogyo Co Ltd | 縮合ピリジン誘導体 |
GB9520092D0 (en) | 1995-10-02 | 1995-12-06 | Hoechst Roussel Ltd | Chemical compounds |
AU2896097A (en) | 1996-05-10 | 1997-12-05 | Novartis Ag | Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation |
DE19636974A1 (de) | 1996-09-12 | 1998-03-19 | Hoechst Ag | 2-Cyano-3,5-dihydroxy-hex-2-en- carbonsäureamidderivate |
JPH10231289A (ja) | 1996-12-06 | 1998-09-02 | Kyowa Hakko Kogyo Co Ltd | 四環系キノリン誘導体 |
US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
US20040265375A1 (en) * | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
BRPI1010084A2 (pt) * | 2009-06-19 | 2015-08-25 | Knopp Neurosciences Inc | Método para tratar esclerose lateral amiotrófica em um paciente |
CN104666272A (zh) * | 2009-09-18 | 2015-06-03 | 赛诺菲 | 稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂 |
UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат |
-
2014
- 2014-11-21 CN CN201480073657.9A patent/CN105916522A/zh active Pending
- 2014-11-21 WO PCT/US2014/066766 patent/WO2015077535A2/en active Application Filing
- 2014-11-21 KR KR1020167016071A patent/KR20160079123A/ko not_active Application Discontinuation
- 2014-11-21 CA CA2930429A patent/CA2930429A1/en not_active Abandoned
- 2014-11-21 MX MX2016006678A patent/MX2016006678A/es unknown
- 2014-11-21 EA EA201691057A patent/EA201691057A1/ru unknown
- 2014-11-21 AU AU2014352920A patent/AU2014352920A1/en not_active Abandoned
- 2014-11-21 US US15/038,185 patent/US20160287549A1/en not_active Abandoned
- 2014-11-21 TN TN2016000197A patent/TN2016000197A1/en unknown
- 2014-11-21 JP JP2016530840A patent/JP2016537360A/ja active Pending
- 2014-11-21 EP EP14819148.9A patent/EP3071199A2/en not_active Withdrawn
-
2016
- 2016-05-08 IL IL245541A patent/IL245541A0/en unknown
- 2016-05-16 PH PH12016500903A patent/PH12016500903A1/en unknown
- 2016-05-18 CL CL2016001192A patent/CL2016001192A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160079123A (ko) | 2016-07-05 |
WO2015077535A3 (en) | 2015-08-20 |
AU2014352920A1 (en) | 2016-06-23 |
IL245541A0 (en) | 2016-06-30 |
JP2016537360A (ja) | 2016-12-01 |
TN2016000197A1 (en) | 2017-10-06 |
CL2016001192A1 (es) | 2017-01-13 |
MX2016006678A (es) | 2016-09-13 |
CA2930429A1 (en) | 2015-05-28 |
EP3071199A2 (en) | 2016-09-28 |
US20160287549A1 (en) | 2016-10-06 |
PH12016500903A1 (en) | 2016-06-20 |
WO2015077535A2 (en) | 2015-05-28 |
CN105916522A (zh) | 2016-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
PH12016501601A1 (en) | Cyclopropylamines as lsd1 inhibitors | |
MX2020003702A (es) | Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
PH12015502075B1 (en) | Treatment of cataplexy | |
EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
TW201613860A (en) | Cyclopropylamines as LSD1 inhibitors | |
EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
EA201591705A1 (ru) | Композиции и способы для диагностики и лечения рака печени | |
BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
EA201600026A1 (ru) | Бактериальная гиалуронидаза и способ ее производства | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
MX2016005393A (es) | Metodos para tratar vhc. | |
PH12016500903A1 (en) | Novel methods for treating neurodegenerative diseases | |
EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
GEP201706764B (en) | Quinazolin-thf-amines as pde1 inhibitors | |
EA201491581A1 (ru) | Везикулярные композиции | |
EA201690446A1 (ru) | Лечение множественной миеломы | |
EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
IN2014DN07989A (ru) | ||
UA114811C2 (uk) | Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу | |
EA201690709A1 (ru) | Применение одипарцила в лечении мукополисахаридоза |